Novartis unveils new class of preclinical antimalarial
This article was originally published in Scrip
Executive Summary
Novartis and its collaborators have unveiled a new class of promising antimalarials – the spiroindolones. The lead candidate in the class, NITD609, yielded promising efficacy and safety data in in vitro and in vivo preclinical models, the company reported in Science on 3 September.